Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

A study demonstrates that radiologic imaging significantly alters management strategies in nearly half of high-risk cutaneous ...

The FDA has approved Akeso Inc.’s penpulimab-kcqx in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic NPC.

The antibody is to treat adult recurrent or metastatic non-keratinising nasopharyngeal carcinoma (NPC) in conjunction with ...